Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent

Xenobiotica

Volumn 45, Issue 12, 2015, Pages 1105-1115

  Hasegawa, Masatoshi ^a   Chino, Yukihiro ^a   Horiuchi, Nobuko ^a   Hachiuma, Kenji ^a   Ishida, Masahiro ^a   Fukasawa, Yoshiki ^a   Nakai, Yasuhiro ^a   Yamaguchi, Jun Ichi ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Autoradiography; disposition; luseogliflozin; metabolism; renal distribution; SGLT2 inhibitor

Indexed keywords

GLUCURONIDE; LUSEOGLIFLOZIN; PHLORIZIN; SODIUM GLUCOSE COTRANSPORTER 2; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; PLASMA PROTEIN; SGLT2 PROTEIN, RAT; SORBITOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; HUMAN; HUMAN CELL; KIDNEY CORTEX; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; CHEMISTRY; FECES; HYPERGLYCEMIA; INTESTINE ABSORPTION; KIDNEY; METABOLISM; OXIDATION REDUCTION REACTION; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; BIOTRANSFORMATION; BLOOD PROTEINS; DOGS; FECES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INTESTINAL ABSORPTION; KIDNEY; OXIDATION-REDUCTION; PHLORHIZIN; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL; TISSUE DISTRIBUTION;

EID: 84945488784     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2015.1042947     Document Type: Article

References (18)

1. Hediger MA, Rhoads DB. (1994). Molecular physiology of sodium glucose cotransporters. Physiol Rev 74: 993-1026
2. Kadokura T, Saito M, Utsuno A, et al. (2011). Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int 2: 172-82
3. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (2010). (1 S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53: 3247-61
4. Kanai Y, Lee WS, You G, et al. (1994). The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest 93: 397-404
5. Kim GW, Chung SH. (2014). Clinical implication of SGLT2 inhibitors in type 2 diabetes. Arch Pharm Res 37: 957-66
6. Kurosaki E, Ogasawara H. (2013). Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 139: 51-9
7. Liu J, Lee T, DeFronzo R. (2012). Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61: 2199-204
8. Mizuno-Yasuhira A, Nakai Y, Gunji E, et al. (2014). A strategy for assessing potential drug-drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans. Drug Metab Dispos 42: 1456-65
9. Musso G, Gambino R, Cassader M, et al. (2012). A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44: 375-93
10. Rahmoune H, Thompson PW, Ward JM, et al. (2005). Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427-34
11. Sabolic I, Vrhovac I, Eror DB, et al. (2012). Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 15: C1174-88
12. Sarashina A, Koiwai K, Seman LJ, et al. (2013). Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28: 213-19
13. Sasaki T, Seino Y, Fukatsu A, Sakai S, et al. (2014). Safety, Pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther 31: 345-61
14. Scheen AJ. (2014). Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet 53: 295-304
15. Schwab D, Portron A, Backholer Z, et al. (2013). A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet 52: 463-73
16. Seino Y. (2014). Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 15: 2741-9
17. Washburn WN, Poucher SM. (2013). Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22: 463-86
18. Yamamoto K, Uchida S, Kitano K, et al. (2011). TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 164: 181-91